• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Recognized Consensus Standards

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

New Search Back To Search Results
Recognition List Number: 026 Publication Date: 03/18/2011 

Part B: SUPPLEMENTARY INFORMATION

Recognition Number 3-87: ASTM F 2477-07, Standard Test Methods for in vitro Pulsatile Durability. (Cardiovascular)

Date of Standard: 2007. 
Address of Standards Organization:
  ASTM International (ASTM)
  100 Barr Harbor Drive
  West Conshohocken, PA 19428-2959
 
CDRH Office and Division Associated with Recognized Standards:
OFFICE OF DEVICE EVALUATION (ODE)
DIVISION OF CARDIOVASCULAR DEVICES (DCD)
Devices Affected:
Vascular stents (including coronary and peripheral, and bare metal and drug-eluting stents)
Processes Affected:
PMA, IDE, PDP, HDE, Design Control Input, Quality System Regulation
Extent of Recognition:
Complete standard

NOTE: This standard identifies critical parameters for endovascular systems and provides guidance on the development of appropriate test methods. It does not contain acceptance criteria for the parameters.
Related CFR Citations and Product Codes:
Regulation
Number
Device Name Device
Class
Product
Code
Unclassified Coronary Drug-Eluting Stent Class 3 NIQ
Unclassified Stent, Carotid Class 3 NIM
Unclassified Stent, Coronary Class 3 MAF
Unclassified Stent, Iliac Class 3 NIO
Unclassified Stent, Renal Class 3 NIN
Unclassified Stent, Superficial Femoral Artery Class 3 NIP
 
Relevant Guidance:
Guidance for Industry and FDA Staff - Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems
FDA Technical Contact:
  Kenneth Cavanaugh
  FDA/CDRH/ODE
  10903 New Hampshire Avenue Building 66, Room 1208
  Silver Spring MD 20993
  301/796-6377
  Email: kenneth.cavanaugh@fda.hhs.gov
-
-